Business Segments · Research and development expense
Innovative Medicine — Research and development expense
Johnson & Johnson Innovative Medicine — Research and development expense decreased by 18.8% to $2.81B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.4%, from $2.55B to $2.81B. Over 3 years (FY 2022 to FY 2025), Innovative Medicine — Research and development expense shows relatively stable performance with a 0.5% CAGR.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026Apr 22, 2026
Rolls up toR&D
How to read this metric
Higher investment is generally positive for long-term growth, provided it leads to successful pipeline progression.
Detailed definition
Tracks the investment in scientific research, clinical trials, and product development within the Innovative Medicine se...
Peer comparison
Standard 'R&D Expense' reported by pharmaceutical companies for their drug development segments.
Metric ID:
jnj_segment_innovative_medicine_research_and_development_expenseHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.91B | $2.91B | $2.91B | $2.91B | $2.99B | $2.99B | $2.99B | $2.99B | $2.90B | $2.72B | $4.21B | $3.70B | $2.55B | $2.87B | $2.94B | $3.47B | $2.81B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +2.8% | +0.0% | +0.0% | +0.0% | -3.2% | -6.0% | +54.8% | -12.2% | -31.1% | +12.6% | +2.6% | +17.7% | -18.8% |
| YoY Change | — | — | — | — | +2.8% | +2.8% | +2.8% | +2.8% | -3.2% | -9.0% | +40.9% | +23.6% | -12.0% | +5.4% | -30.1% | -6.3% | +10.4% |
Range$2.55B – $4.21B
CAGR-0.8%
Avg YoY Growth+2.4%
Median YoY Growth+2.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — research and development expense?
- Johnson & Johnson (JNJ) reported innovative medicine — research and development expense of $2.81B in Q1 2026.
- How has Johnson & Johnson's innovative medicine — research and development expense changed year-over-year?
- Johnson & Johnson's innovative medicine — research and development expense increased by 10.4% year-over-year, from $2.55B to $2.81B.
- What is the long-term trend for Johnson & Johnson's innovative medicine — research and development expense?
- Over 3 years (2022 to 2025), Johnson & Johnson's innovative medicine — research and development expense has grown at a 0.5% compound annual growth rate (CAGR), from $11.64B to $11.83B.
- What does innovative medicine — research and development expense mean?
- The amount spent on research and development for new medicines within the segment.